New Tests
Catch Up with New and Enhanced Tests in All Methodologies
Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. We are continually refining and adding new assays in hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.
Please Review Our List of Recently Launched Tests:
- PD-L1 SP142 FDA (TECENTRIQ®) for TNBC (3-11-19)
- Pan-TRK IHC (2-11-19)
- Albumin RNA ISH (2-11-19)
- NUT IHC (2-11-19)
- Lung NGS Fusion Profile (12-24-18)
- NTRK NGS Fusion Profile (12-24-18)
- BCL2 (SP66) IHC (12-17-18)
- CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile (11-13-18)
- NeoCOMPLETETM (new 11-12-18)
- 11q Aberration in NHL (new 10-4-18)
- ICOS (new 8-29-18)
- NGFR (new 8-24-18)
- TP63 Rearrangement (new 8-21-18)
- B-ALL MRD Flow Panel (new 7-30-18)
- BCL10 IHC (new 7-23-18)
- PD-L1, 22C3 FDA (KEYTRUDA®) for Cervical (new 6-18-18)
- Sezary T-Cell Add-On Flow Panel (new 6-18-18)
- CDKN2A (p16) Deletion FISH for ALL (new 3-8-18)
- PPM1D Mutation Analysis (new 1-25-18)
- CDK2NA (p16) Deletion for Mesothelioma (new 10-10-17)
- PD-L1, 22C3 FDA (KEYTRUDA®) IHC for Gastric/GEA (new 9-29-17)
- NeoTYPE® GI Predictive Profile (new 7-17-17)